{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:00:44Z","timestamp":1788454844059,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"clinical trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University","award":["2022-LCYJ-PY-48 ;2023-LCYJ-MS-32"],"award-info":[{"award-number":["2022-LCYJ-PY-48 ;2023-LCYJ-MS-32"]}]},{"name":"the Hospital Pharmacy Department of the Chinese Pharmaceutical Association","award":["CPA-Z05-ZC-2023002"],"award-info":[{"award-number":["CPA-Z05-ZC-2023002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11096-025-01998-w","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T06:26:44Z","timestamp":1760423204000},"page":"1920-1932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetics of imipenem and target attainment of pharmacokinetic\/pharmacodynamic indices in Chinese adults with febrile neutropenia and hematological malignancies"],"prefix":"10.1007","volume":"47","author":[{"given":"Qi","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"9","key":"1998_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090785","volume":"12","author":"PG Cojutti","year":"2020","unstructured":"Cojutti PG, Candoni A, Lazzarotto D, et al. Population pharmacokinetics of continuous-infusion meropenem in febrile neutropenic patients with hematologic malignancies: dosing strategies for optimizing empirical treatment against Enterobacterales and P. aeruginosa. Pharmaceutics. 2020;12(9): 785. https:\/\/doi.org\/10.3390\/pharmaceutics12090785.","journal-title":"Pharmaceutics"},{"issue":"6","key":"1998_CR2","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1086\/339215","volume":"34","author":"WT Hughes","year":"2002","unstructured":"Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730\u201351. https:\/\/doi.org\/10.1086\/339215.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1998_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10096-003-0894-6","volume":"22","author":"E Velasco","year":"2003","unstructured":"Velasco E, Byington R, Martins CA, et al. Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center. Eur J Clin Microbiol Infect Dis. 2003;22(3):137\u201343. https:\/\/doi.org\/10.1007\/s10096-003-0894-6.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"1998_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199531","volume":"13","author":"C Garcia-Vidal","year":"2018","unstructured":"Garcia-Vidal C, Cardozo-Espinola C, Puerta-Alcalde P, et al. Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. PLoS ONE. 2018;13(6): e0199531. https:\/\/doi.org\/10.1371\/journal.pone.0199531.","journal-title":"PLoS ONE"},{"issue":"1","key":"1998_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12879-020-05131-2","volume":"20","author":"DH Shin","year":"2020","unstructured":"Shin DH, Shin DY, Kang CK, et al. Risk factors for and clinical outcomes of carbapenem non-susceptible gram negative bacilli bacteremia in patients with acute myelogenous leukemia. BMC Infect Dis. 2020;20(1):404. https:\/\/doi.org\/10.1186\/s12879-020-05131-2.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"1998_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2165\/00003495-199244030-00008","volume":"44","author":"MM Buckley","year":"1992","unstructured":"Buckley MM, Brogden RN, Barradell LB, et al. Imipenem\/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1992;44(3):408\u201344. https:\/\/doi.org\/10.2165\/00003495-199244030-00008.","journal-title":"Drugs"},{"issue":"4","key":"1998_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/00003088-200948040-00005","volume":"48","author":"M Fern\u00e1ndez de Gatta Mdel","year":"2009","unstructured":"Fern\u00e1ndez de Gatta Mdel M, Santos Buelga D, S\u00e1nchez Navarro A, et al. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic\/pharmacodynamic analysis. Clin Pharmacokinet. 2009;48(4):273\u201380. https:\/\/doi.org\/10.2165\/00003088-200948040-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1998_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1128\/aac.00943-08","volume":"53","author":"JS Bubalo","year":"2009","unstructured":"Bubalo JS, Munar MY, Cherala G, et al. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53(2):428\u201334. https:\/\/doi.org\/10.1128\/aac.00943-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1998_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/00365540151060941","volume":"33","author":"A Nyhl\u00e9n","year":"2001","unstructured":"Nyhl\u00e9n A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ceftazidime in febrile neutropenic patients. Scand J Infect Dis. 2001;33(3):222\u20136. https:\/\/doi.org\/10.1080\/00365540151060941.","journal-title":"Scand J Infect Dis"},{"issue":"5","key":"1998_CR10","first-page":"487","volume":"20","author":"XJ Fu","year":"2020","unstructured":"Fu XJ, Yang HB, Lin LM. Clinical characteristics and influencing factors of vancomycin blood concentration in patients with hematological diseases. Chin J Infect Chemother. 2020;20(5):487\u201392.","journal-title":"Chin J Infect Chemother"},{"issue":"3","key":"1998_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/ftd.0000000000000270","volume":"38","author":"K Hirai","year":"2016","unstructured":"Hirai K, Ihara S, Kinae A, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance. Ther Drug Monit. 2016;38(3):393\u20137. https:\/\/doi.org\/10.1097\/ftd.0000000000000270.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1998_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5414\/cp201739","volume":"51","author":"R Ogawa","year":"2013","unstructured":"Ogawa R, Kobayashi S, Sasaki Y, et al. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection. Int J Clin Pharmacol Ther. 2013;51(5):357\u201366. https:\/\/doi.org\/10.5414\/cp201739.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"1998_CR13","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/cid\/cis210","volume":"54","author":"U Theuretzbacher","year":"2012","unstructured":"Theuretzbacher U. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis. 2012;54(12):1785\u201392. https:\/\/doi.org\/10.1093\/cid\/cis210.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1998_CR14","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s11096-011-9567-1","volume":"33","author":"BJ Balderson","year":"2011","unstructured":"Balderson BJ, Yates ME, Patil NP, et al. Evaluation of doripenem utilization and susceptibilities at a large urban hospital. Int J Clin Pharm. 2011;33(6):958\u201363. https:\/\/doi.org\/10.1007\/s11096-011-9567-1.","journal-title":"Int J Clin Pharm"},{"issue":"8","key":"1998_CR15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072\u201383. https:\/\/doi.org\/10.1093\/cid\/ciu027.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1998_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ijantimicag.2010.01.022","volume":"35","author":"JA Roberts","year":"2010","unstructured":"Roberts JA, Hope WW, Lipman J. Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int J Antimicrob Agents. 2010;35(5):419\u201320. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.01.022.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"1998_CR17","first-page":"543","volume":"28","author":"XY Zhu Yan","year":"2012","unstructured":"Zhu Yan XY. Research progress on the pharmacokinetics\/pharmacodynamics of \u03b2-lactam\/\u03b2-lactamase inhibitor combination antibiotics. Chin J Clin Pharmacol. 2012;28(7):543\u20136.","journal-title":"Chin J Clin Pharmacol"},{"issue":"1","key":"1998_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","volume":"26","author":"WA Craig","year":"1998","unstructured":"Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis: Off Publ Infect Dis Soc Am. 1998;26(1):1\u201310. https:\/\/doi.org\/10.1086\/516284. (quiz 1\u20132).","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"1","key":"1998_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1345\/aph.1E271","volume":"39","author":"RE Ariano","year":"2005","unstructured":"Ariano RE, Nyhl\u00e9n A, Donnelly JP, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005;39(1):32\u20138. https:\/\/doi.org\/10.1345\/aph.1E271.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1998_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40560-020-00504-w","volume":"8","author":"C Scharf","year":"2020","unstructured":"Scharf C, Liebchen U, Paal M, et al. The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome. J Intensive Care. 2020;8(1):86. https:\/\/doi.org\/10.1186\/s40560-020-00504-w.","journal-title":"J Intensive Care"},{"issue":"Suppl 1","key":"1998_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00228-010-0974-3","volume":"67","author":"F Bellanti","year":"2011","unstructured":"Bellanti F, Della Pasqua O. Modelling and simulation as research tools in paediatric drug development. Eur J Clin Pharmacol. 2011;67(Suppl 1):75\u201386. https:\/\/doi.org\/10.1007\/s00228-010-0974-3.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1998_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40262-013-0085-2","volume":"52","author":"R Narwal","year":"2013","unstructured":"Narwal R, Roskos LK, Robbie GJ. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus. Clin Pharmacokinet. 2013;52(11):1017\u201327. https:\/\/doi.org\/10.1007\/s40262-013-0085-2.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"1998_CR23","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1086\/518137","volume":"45","author":"GL Drusano","year":"2007","unstructured":"Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2007;45(Suppl 1):S89-95. https:\/\/doi.org\/10.1086\/518137.","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"3","key":"1998_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241\u201357. https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005.","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"1998_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/bcp.13431","volume":"84","author":"JJ Mao","year":"2018","unstructured":"Mao JJ, Jiao Z, Yun HY, et al. External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients. Br J Clin Pharmacol. 2018;84(1):153\u201371. https:\/\/doi.org\/10.1111\/bcp.13431.","journal-title":"Br J Clin Pharmacol"},{"key":"1998_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.781892","volume":"12","author":"PG Cojutti","year":"2021","unstructured":"Cojutti PG, Gatti M, Rinaldi M, et al. Impact of maximizing Css\/MIC ratio on efficacy of continuous infusion meropenem against documented gram-negative infections in critically ill patients and population pharmacokinetic\/pharmacodynamic analysis to support treatment optimization. Front Pharmacol. 2021;12: 781892. https:\/\/doi.org\/10.3389\/fphar.2021.781892.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1998_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.diagmicrobio.2007.01.004","volume":"58","author":"CA DeRyke","year":"2007","unstructured":"DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis. 2007;58(3):337\u201344. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2007.01.004.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"1998_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki079","volume":"55","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55(5):601\u20137. https:\/\/doi.org\/10.1093\/jac\/dki079.","journal-title":"J Antimicrob Chemother"},{"key":"1998_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijid.2016.06.017","volume":"50","author":"O Asuphon","year":"2016","unstructured":"Asuphon O, Montakantikul P, Houngsaitong J, et al. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic\/pharmacodynamic (PK\/PD) simulation. Int J Infect Dis. 2016;50:23\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2016.06.017.","journal-title":"Int J Infect Dis"},{"issue":"9","key":"1998_CR30","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/jcph.1865","volume":"61","author":"ED Por","year":"2021","unstructured":"Por ED, Akers KS, Chung KK, et al. Population pharmacokinetic modeling and simulations of imipenem in burn patients with and without continuous venovenous hemofiltration in the Military Health System. J Clin Pharmacol. 2021;61(9):1182\u201394. https:\/\/doi.org\/10.1002\/jcph.1865.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1998_CR31","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/cts.13158","volume":"15","author":"M Patel","year":"2022","unstructured":"Patel M, Bellanti F, Daryani NM, et al. Population pharmacokinetic\/pharmacodynamic assessment of imipenem\/cilastatin\/relebactam in patients with hospital-acquired\/ventilator-associated bacterial pneumonia. Clin Transl Sci. 2022;15(2):396\u2013408. https:\/\/doi.org\/10.1111\/cts.13158.","journal-title":"Clin Transl Sci"},{"key":"1998_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/B978-0-12-420117-0.00003-7","volume":"122","author":"MH Hanigan","year":"2014","unstructured":"Hanigan MH. Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Adv Cancer Res. 2014;122:103\u201341. https:\/\/doi.org\/10.1016\/B978-0-12-420117-0.00003-7.","journal-title":"Adv Cancer Res"},{"issue":"2 Pt 2","key":"1998_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/01.hyp.37.2.547","volume":"37","author":"AP Zou","year":"2001","unstructured":"Zou AP, Li N, Cowley AW Jr. Production and actions of superoxide in the renal medulla. Hypertension (Dallas, Tex: 1979). 2001;37(2 Pt 2):547\u201353. https:\/\/doi.org\/10.1161\/01.hyp.37.2.547.","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"1998_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28031447","author":"J Va\u0161kov\u00e1","year":"2023","unstructured":"Va\u0161kov\u00e1 J, Ko\u010dan L, Va\u0161ko L, et al. Glutathione-related enzymes and proteins: a review. Molecules. 2023. https:\/\/doi.org\/10.3390\/molecules28031447.","journal-title":"Molecules"},{"key":"1998_CR35","unstructured":"Chinese Society of Hematology CMDAHPB. Clinical guidelines for the use of antimicrobial agents in patients with neutropenia and fever in China (2020 edition). Chin J Hematol. 2020;41(12):969\u201378."},{"issue":"5","key":"1998_CR36","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.apsb.2019.02.005","volume":"9","author":"X Huo","year":"2019","unstructured":"Huo X, Meng Q, Wang C, et al. Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs). Acta Pharm Sin B. 2019;9(5):986\u201396. https:\/\/doi.org\/10.1016\/j.apsb.2019.02.005.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"1998_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ajps.2018.11.006","volume":"15","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Huo X, Wang C, et al. Organic anion transporters also mediate the drug-drug interaction between imipenem and cilastatin. Asian J Pharm Sci. 2020;15(2):252\u201363. https:\/\/doi.org\/10.1016\/j.ajps.2018.11.006.","journal-title":"Asian J Pharm Sci"},{"key":"1998_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.938813","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang C, Wang C, Wu J, et al. JBP485, a dual inhibitor of organic anion transporters (OATs) and renal dehydropeptidase-I (DHP-I), protects against imipenem-induced nephrotoxicity. Front Pharmacol. 2022;13: 938813. https:\/\/doi.org\/10.3389\/fphar.2022.938813.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1998_CR39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/bcp.12901","volume":"81","author":"JG van Hasselt","year":"2016","unstructured":"van Hasselt JG, Rizk ML, Lala M, et al. Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. Br J Clin Pharmacol. 2016;81(6):1113\u201323. https:\/\/doi.org\/10.1111\/bcp.12901.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1998_CR40","first-page":"318","volume":"43","author":"Q Rao","year":"2023","unstructured":"Rao Q, Zhang J, Wang S, et al. Analysis of factors influencing the blood concentration of biapenem in patients with malignant hematological diseases. Chin J Hosp Pharm. 2023;43(3):318\u201322.","journal-title":"Chin J Hosp Pharm"},{"issue":"4","key":"1998_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000057382","volume":"24","author":"M Cirillo","year":"1998","unstructured":"Cirillo M, Anastasio P, Spitali L, et al. Effects of a meat meal on renal sodium handling and sodium balance. Miner Electrolyte Metab. 1998;24(4):279\u201384. https:\/\/doi.org\/10.1159\/000057382.","journal-title":"Miner Electrolyte Metab"},{"issue":"11","key":"1998_CR42","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/bf01700408","volume":"16","author":"A Nyhl\u00e9n","year":"1997","unstructured":"Nyhl\u00e9n A, Ljungberg B, Nilsson-Ehle I, Swedish Study Group. Pharmacokinetics of meropenem in febrile neutropenic patients. Eur J Clin Microbiol Infect Dis: Off Publ Eur Soc Clin Microbiol. 1997;16(11):797\u2013802. https:\/\/doi.org\/10.1007\/bf01700408.","journal-title":"Eur J Clin Microbiol Infect Dis: Off Publ Eur Soc Clin Microbiol"},{"issue":"5","key":"1998_CR43","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/ejhpharm-2022-003403","volume":"31","author":"J Bai","year":"2024","unstructured":"Bai J, Wen A, Li Z, et al. Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients. Eur J Hosp Pharm. 2024;31(5):434\u20139. https:\/\/doi.org\/10.1136\/ejhpharm-2022-003403.","journal-title":"Eur J Hosp Pharm"},{"issue":"5","key":"1998_CR44","first-page":"432","volume":"38","author":"Y Li","year":"2022","unstructured":"Li Y, Zheng B, L\u00fc Y, et al. CHINET bacterial resistance surveillance (CARST) study: 2019\u20132020 report on Gram-negative bacteria. Chin J Clin Pharmacol. 2022;38(5):432\u201352.","journal-title":"Chin J Clin Pharmacol"},{"issue":"4","key":"1998_CR45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3892\/br.2016.598","volume":"4","author":"H Jin","year":"2016","unstructured":"Jin H, Qiu F, Ji HJ, et al. Analysis of drug resistance in 1,861 strains of Acinetobacter baumannii. Biomed Rep. 2016;4(4):463\u20136. https:\/\/doi.org\/10.3892\/br.2016.598.","journal-title":"Biomed Rep"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01998-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01998-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01998-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:07:57Z","timestamp":1763554077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01998-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1998"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01998-w","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Nanjing Drum Tower Hospital (approval number: 2021-583-01) and was registered at ClinicalTrials.gov (NCT05665478). Written informed consent was obtained from all participants, and the study complied with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}